jRCT2080224839终止3 期
A combination study on WP-1303 or placebo and timolol ophthalmic solution in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH)
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, Randomized, Double-masked, Parallel-group
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Patients with POAG or OH.
- •IOP is less than 35mmHg for both eyes.
- •IOP aftre timolol treated is greater than or equal 18mmHg.
排除标准
- •Patients who have visual acuity of less than 0.
- •Presence of active eye disease (eg., uveitis, ocular infection, severe dry eye).
- •Pregnant women, lactating women or women who desire to be pregnant.
- •Patients who is judged inappropriate to participate in the study by investigator or sub-investigator.
结局指标
主要结局
-
safety efficacy efficacy:intraocular pressure safety:adverse event and adverse drug reaction
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
WP-1303 Phase 3 combination studyjRCT2080224837Wakamoto pharmaceutical Co., Ltd.280
终止
3 期
WP-1303 Phase 3 comparison studyjRCT2080224836Wakamoto pharmaceutical Co., Ltd280
已完成
3 期
A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumabJPRN-UMIN000027938Japan Breast Cancer Research Group446
进行中（未招募）
3 期
JBCRG-M06(EMERALD)HER2-positive progressive-recurrent breast cancerJPRN-jRCTs021180027Yamashita Toshinari480
终止
3 期
WP-1303 Phase 3 combination studyprimary open-angle glaucoma, ocular hypertensionJPRN-jRCT2080224839Wakamoto pharmaceutical Co., Ltd.180